Skip to main content
Premium Trial:

Request an Annual Quote

Response Biomedical Raises $11M in Offering

NEW YORK (GenomeWeb News) – Response Biomedical said today that it has grossed C$12.7 million ($11.1 million) through a public offering, and it plans to use the funds for general operating costs and for capital acquisitions.

The company said it issued 73,333,333 units at a price of C$0.15 per unit, and that it concurrently issued an additional 11 million units pursuant to the exercise-in-full of an over-allotment option it granted to the underwriter.

Each unit consists of one common share and one-half of one common warrant, with each warrant entitling the shareholder to buy an additional common share at C$.25.

Response also granted 2.53 million common share warrants to the underwriter, with each broker's warrant entitling the holder to buy one common share at $C.25 within 24 months of the closing date of the offering.

Response Biomedical also said it expects the sale to move the Toronto Stock Exchange to terminate a delisting review of the company's shares.

Filed under

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.